Cerba HealthCare Acquires Lifebrain

November 05, 2021

Paris – Paul Hastings LLP, a leading global law firm, represented EQT and Cerba HealthCare in connection with the acquisition of a majority stake in Lifebrain.

Cerba HealthCare, a reference player in the field of medical diagnosis, has completed the acquisition of Lifebrain in Italy following an exclusive agreement reached this summer with the shareholder, European Laboratory Solutions S.a.r.l., a company indirectly held by Investindustrial VI L.P.

Based in France, Cerba HealthCare has sound positions in Europe and Africa where it holds historical track record in routine and specialty clinical pathology. Cerba HealthCare also has global presence and expertise in clinical pathology for clinical trials, which enables the company to validate and improve the effectiveness of new treatments and vaccines.

Lifebrain is a leading industry player in Italy where it is recognized for its unparalleled experience in acquisitions and its strong geographical presence that includes a network of three hubs and close to 360 sites.

Cerba HealthCare welcomed EQT as new majority shareholder in June 2021.

Paul Hastings’ team was led by partner Arthur de Baudry d'Asson and included associates Nicolas Lovas and Mathilde Carré on corporate matters, as well as partner Allard de Waal and associate Alban Castarède on tax matters.

Paul Hastings’ team also advised EQT for its investment in Cerba Heath Care in June 2021.

About Paul Hastings
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.
For more information please visit our website: www.paulhastings.com